ClinicalTrials.gg
Enrolling by invitationNCT07042074SNACUpdated Nov 18, 2026

Use of Augmented Reality and Virtual Reality During Cognitive Behavioral Therapy for Needle Phobia

An interventional study of Mixed reality (XR) Exposure Therapy in Needle Phobia, Virtual Reality and Cognitive Behavior Treatment, sponsored by Stanford University. Enrolling by invitation at 1 site in United States. Open to participants aged 11 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Stanford University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 18, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
11 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 585 studies in Behavior with a site in United States — 87 open to participants now, 118 under way, 2 of them phase 3. Behavior · United States.

Planned enrollment
447th of 495
20 · median 121
Started
2026
with 32 others
No phase
431 of 585
74 open now
Primary completion
2027-04
later than 53 of 116 live
Registered
521st of 585
by date
Lead sponsor
9 of 585
Stanford University

Among the 585 studies in Behavior with a site in United States, this one is the 447th largest by planned enrollment of the 495 interventional ones that give a count, is one of 33 that started in 2026, is one of 431 with no phase, reaches primary completion later than 53 of the 116 other live ones, and was the 521st registered.

Behavior

1,579 studies on the registry are indexed under Behavior; 314 are open to participants now.

Browse Behavior studies →

Open to participants now

87 of the 585 studies in Behavior with a site in United States are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Behavior studies recruiting now, 77 (44%) set no upper age limit and 72 (41%) stop at 75 or younger; 58 take children under 18; 99 take healthy volunteers.

This study: 11 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 585 studies in Behavior with a site in United States, or all of them as a file.
02

Study summary

This case series study seeks to evaluate the use of a Spatial Computing Device and Augmented Reality (AR) and Virtual Reality (VR) as an exposure therapy modality for children and adolescents with needle and blood-injection-injury phobia. This study will take place at Lucile Packard Children's Hospital (LPCH) and Stanford Hospital (Stanford University, Palo Alto, CA).

Read the detailed description

Needle phobia and Blood-Injection-Injury phobia are anxieties that are observed in children, adolescents, and adults undergoing medical/surgical procedures and the use of needles. These phobias can lead to an impediment of care for children or adolescents and may impact their ability to participate in care and/or receive essential treatments. This can lead to significant delays in treatment of individuals and medical trauma for patients who can only receive treatments/procedures using needles after undergoing sedation. Although treatment protocols exist for treating needle and blood-injection-injury phobia in adults, the literature regarding treatment in children and adolescents is limited. Additionally, the use of medications for management of needle phobia can lead to increased medical complications and may not resolve the underlying cause of needle phobia. Recent technological developments have led to the use of virtual reality exposure therapy (XRET) for treating needle and blood-injection-injury phobia, however few studies have been performed in children, and the literature regarding anxiety and clinical outcomes using this treatment modality is lacking in this population. Further, newly developed spatial computing and XR (Mixed Reality) devices have led to advancements in immersion and personalization of images/videos, and as such may lead to increased engagement and clinical efficacy for patients participating in XRET.

The study aims to evaluate the effectiveness of combining cognitive behavioral therapy (CBT) and extended reality exposure therapy (XRET) for treating needle and blood-injection-injury (BII) phobia in children and adolescents. The intervention requires direct observation of human participants' psychological and physiological responses to exposures. These measurements, including anxiety levels and sympathetic/parasympathetic activity, can only be obtained from human subjects to assess treatment efficacy.

03

Conditions studied

  • Needle Phobia
  • Virtual Reality
  • Cognitive Behavior Treatment
04

Who can participate

Ages eligible
11 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients between the ages of 11-17
  2. Fear of needle
  3. Patients screened with the modified APA severity Measure for Specific Phobia (blood, needles, or injections), and have an individual phobia score rated as moderate, severe, or extreme (as described below)

Exclusion criteria

Exclusion Criteria:

  1. Legal guardian not present to obtain consent
  2. Adolescent with a significant neurological condition, or major developmental disability
  3. Adolescent with active infection of the face or hand
  4. A history of severe motion sickness
  5. A history of seizures caused by flashing light
  6. An impending surgery within the last 48 hours
  7. Adolescents who wear glasses and cannot use contacts
  8. Adolescents with physical disabilities that prevent them from using their hands
  9. Patients with substance use disorder in past year
  10. Virtual Reality headsets do not fit.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Cognitive Behavioral Therapy (CBT) + Extended reality exposure therapy (XRET)

    Behavioral: Mixed reality (XR) Exposure Therapy

Interventions

  • BehavioralMixed reality (XR) Exposure Therapy

    Participants will engage in a maximum 8-session intervention combining Cognitive Behavioral Therapy (CBT) and Extended Reality Therapy (XRET) to address needle phobia and blood-injection-injury (BII) phobia. The intervention begins with an initial intake session where the APA-SMS screener results are reviewed. Participants will then undergo VR exposure, with mixed exposure to sham needles in the latter exposure session. Anxiety levels will be assessed using a Visual Analog Scale (VAS-A) during and after each session. If VAS-A score is less or equal to 5, participants will be able to proceed. If VAS-A score is greater than 5, participants will have the option to exit the study or proceed. The final session includes in-person exposure to a real needle, aiming for voluntary vaccination or IV placement. Coping strategies will be discussed at the final session. Participants will be contacted for follow-up assessments at 6 and 12 weeks to evaluate long-term outcomes.

06

What researchers measure

Primary outcomes

  1. Change in anxiety symptoms related to needle phobia and BII

    APA severity Measure for Specific Phobia (APA-SMS) is a validated tool used to assess the severity of specific phobia symptoms, including needle and blood-injection-injury (BII) phobia. The scale has 10 items, rated on a 5-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme). The total score ranges from 0 - 40, with higher scores indicating greater severity of phobia. A change in symptom ratings from moderate/severe/extreme rating to mild/none indicates remission of symptoms by the end of intervention.

    Time frame: Baseline, immediately after the intervention of week 4 and week 5, 6 and 12 weeks after completion of treatment

Secondary outcomes

  1. Skin Conductance Response Density (SCRD)

    Change in sympathetic response to a scripted discussion regarding use of a needle and needle being shown - administered at the beginning of the first session and at the end of the last session.

    Time frame: during the first intervention, week 4, week 5 and last intervention.

  2. Parasympathetic response indexed by Respiratory sinus arrhythmia (RSA)

    Change in parasympathetic response to a scripted discussion regarding use of a needle and needle being shown. Measured via respiratory sinus arrhythmia (RSA) in hertz using chest biometric sensors in 30-second epochs.

    Time frame: during the first intervention, week 4, week 5 and last intervention.

  3. Change in Anxiety after virtual exposure

    Anxiety levels will be measured by a Visual Analogue Scale - Anxiety (VAS-A), where participants rate their anxiety in a scale ranging from 0-10, with 0 representing no anxiety to 10 representing extreme anxiety. Higher scores indicate higher anxiety levels.

    Time frame: Baseline, immediately after the intervention

  4. Change in Anxiety after real exposure

    Anxiety levels will be measured by a Visual Analogue Scale - Anxiety (VAS-A), where participants rate their anxiety in a scale ranging from 0-10, with 0 representing no anxiety to 10 representing extreme anxiety. Higher scores indicate higher anxiety levels.

    Time frame: during intervention, immediately after the intervention

  5. User engagement

    User engagement will be measured by User Engagement Scale (UES) - Short. This scale consists of 12 items that participants will respond to, reflecting their feelings and interactions with the application or platform. Each item is rated on a Likert scale ranging from 1 to 5, where 1 indicates "strongly disagree" and 5 indicates "strongly agree."

    Time frame: Immediately after final intervention

07

Study locations

1 site
  • Lucile Parkard Children's Hospital
    Stanford, California 94304, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Apr 2027, 7 months after the start.

Of 745 non-industry interventional studies with no phase under Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 7 months is below that.

Counting every sponsor, half of 761 studies reached it within 13 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2024
First posted
Jun 27, 2025
StartActual
Sep 18, 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2026→Sep 18, 2026 (actual)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Sep 1, 2026→Sep 18, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07042074
Responsible party
Thomas Caruso (Clinical Professor, Stanford University) — Principal investigator
First posted
Jun 27, 2025
Start date
Sep 18, 2026
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Aaron Lulla, MD, PhD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion